StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Sachin Janardan Sarvade, IDBI Capital Markets and Securities

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

bySachin Janardan Sarvade, IDBI Capital Markets and SecuritiesHorizon: NA (inferred 1 year)2 Nov 2026via NDTV Profit (Live)

Entry₹1,250Inferred
Target₹1,580
Total upside +26.40%
Stop loss₹1,079-13.68% risk
CMP₹1,197.91d ago
Active-4.17%+31.90%upside left 12 mo left
Follow Sachin Janardan Sarvade for new callsGet alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 12 other Long-term calls on ZYDUSLIFESee 541 other Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 7 Nov, 5:28 pm IST
33 supporting10 neutral11 opposing
Supports the BUY call (33)

Zydus Lifesciences' Saroglitazar shows higher MASH resolution rates than placebo in phase 2b trial

NewsCnbc-Tv18·6 Nov · today

(opens in new tab)

Zydus Lifesciences announced positive Phase 2b clinical trial results for Saroglitazar in treating MASH and fibrosis, showing significant resolution of steatohepatitis compared to placebo.

NSE · Press Release·6 Nov · today

(opens in new tab)

Zydus Lifesciences announced positive Phase 2b clinical trial results for Saroglitazar in treating MASH and fibrosis, showing significant resolution of steatohepatitis compared to placebo.

BSE · Company Update·6 Nov · today

(opens in new tab)

Long-term trend bullish — 200-day average rising over the past quarter

Technicals · trend·6 Nov · yesterday

9 other SEBI-registered advisors have active long-term BUY calls on this stock, with 5 issued in the last 14 days

Advisor consensus · same horizon·6 Nov · yesterday

Neutral / worth noting (10)

Zydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

NSE · Outcome of Board Meeting·4 Nov · 3d ago

(opens in new tab)
Weighs against the BUY call (11)

Zydus Lifesciences Q2 net profit falls 26.6% to Rs 925.5 crore

NewsEt-Markets·5 Nov · 2d ago

(opens in new tab)

Zydus Lifesciences Q2 Results: Shares fall after profit drops 27%, margins contract

NewsCnbc-Tv18·4 Nov · 3d ago

(opens in new tab)

Zydus Lifesciences reported Q2 FY27 consolidated net profit of Rs 9,255 million, down 27% year-on-year, with EBITDA down 6% to Rs 18,945 million. Revenue grew 29% to Rs 79,096 million.

BSE · Company Update·4 Nov · 3d ago

(opens in new tab)

Zydus Lifesciences reported Q2 FY27 consolidated net profit of Rs 9,255 million, down 27% year-on-year, and EBITDA of Rs 18,945 million, down 6% year-on-year.

NSE · Press Release·4 Nov · 3d ago

(opens in new tab)

Zydus Lifesciences In Focus As US FDA Flags Data Integrity, Quality Control Issues At Gujarat Plant

NewsNdtv-Profit·26 Oct · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Sachin Janardan Sarvade, IDBI Capital Markets and Securities

Every call and its outcome